Literature DB >> 26508365

Dramatic PSA Increase With Tumor Shrinkage After Initiating Degarelix in Advanced Prostate Cancer.

Nischala Ammannagari1, Chandana Javvaji2, Pongwut Danchaivijitr3, Saby George3.   

Abstract

Entities:  

Keywords:  Degarelix; GnRH antagonists; PSA rise; Prostate cancer; Tumor lysis

Mesh：

Substances：

Year:  2015        PMID： 26508365     DOI： 10.1016/j.clgc.2015.09.012

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  2 in total

1.  Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.

Authors:  Mohammad Hassan Heidari; Abolfazl Movafagh; Mohammad-Amin Abdollahifar; Shabnam Abdi; Mohamadreza Mashhoudi Barez; Hadi Azimi; Afshin Moradi; Amin Bagheri; Matineh Heidari; Jafar Hessam Mohseni; Maryam Tadayon; Hoda Mirsafian; Mahdi Ghatrehsamani
Journal:  Anat Cell Biol       Date:  2017-03-29

Review 2.  Degarelix for treating advanced hormone-sensitive prostate cancer.

Authors:  Friedemann Zengerling; Joachim J Jakob; Stefanie Schmidt; Joerg J Meerpohl; Anette Blümle; Christine Schmucker; Benjamin Mayer; Frank Kunath
Journal:  Cochrane Database Syst Rev       Date:  2021-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.